Pharmacological Abortion in a Pandemic: An Italian Medico-Legal Perspective

The limitations caused by the spread of the SARS-CoV2 virus have had repercussions on the voluntary termination of pregnancy. During the pandemic, Italy issued updated guidelines regarding voluntary termination of pregnancy by means of mifepristone and prostaglandin. This included news concerning the time limit and location in which this procedure could be accessed: updates partially recognize women’s needs, and they are into line with the European parliament’s recent exhortations. However, these updates do not change the previously provided responsibilities that lie with doctors. This article aimed to compare regulations concerning medical abortion in Italy and other countries, with a focus on recent Italian updates in the context of pandemic.

[1]  M. Casini.  La RU486 tra legge 194 e nuove linee di indirizzo sulla interruzione volontaria di gravidanza con Mifepristone e prostaglandine , 2021, Medicina e Morale.

[2]  A. Shander,et al.  Deploying Health Care Providers During the COVID-19 Pandemic , 2021, Disaster medicine and public health preparedness.

[3]  A. Aprile,et al.  The Difficult Balance between Ensuring the Right of Nursing Home Residents to Communication and Their Safety , 2021, International journal of environmental research and public health.

[4]  A. Aprile,et al.  Take-Home Messages from the COVID-19 Pandemic: Strengths and Pitfalls of the Italian National Health Service from a Medico-Legal Point of View , 2020, Healthcare.

[5]  A. Spagnolo.  RU486: è solo una questione medico-farmacologica? , 2020 .

[6]  K. Gemzell‐Danielsson,et al.  Abortion regulation in Europe in the era of COVID-19: a spectrum of policy responses , 2020, BMJ Sexual & Reproductive Health.

[7]  Practice Bulletins—Gynecology,et al.  Medication Abortion up to 70 Days of Gestation. , 2020, Contraception.

[8]  L. Lindberg,et al.  COVID‐19 Abortion Bans and Their Implications for Public Health , 2020, Perspectives on sexual and reproductive health.

[9]  S. Borrero,et al.  The legal and medical necessity of abortion care amid the COVID-19 pandemic , 2020, Journal of law and the biosciences.

[10]  M. Bayefsky,et al.  Abortion during the Covid-19 Pandemic - Ensuring Access to an Essential Health Service. , 2020, The New England journal of medicine.

[11]  M. Iadicicco.  Aborto farmacologico ed emergenza sanitaria da Covid-19 , 2020 .

[12]  The use of mifepristone for medical abortion. , 2019, The Australian & New Zealand journal of obstetrics & gynaecology.

[13]  W. H. Pearse,et al.  American College of Obstetricians and Gynecologists , 2018, Definitions.

[14]  M. S. Morehead,et al.  Mifepristone , 2001, Reactions Weekly.

[15]  C. Dyer.  Decriminalisation of abortion , 2017, British Medical Journal.

[16]  E. Schaff.  Mifepristone: ten years later. , 2010, Contraception.

[17]  D. Harrison,et al.  Analysis of Severe Adverse Events Related to the Use of Mifepristone as an Abortifacient , 2006, The Annals of pharmacotherapy.

[18]  S. Henshaw,et al.  Perspectives on Sexual and Reproductive Health Registered Regimens Mifepristone for Early Medical Abortion: Experiences in France, Great Britain and Sweden , 2022 .

[19]  M. Creinin.  Medical abortion regimens: historical context and overview. , 2000, American journal of obstetrics and gynecology.

[20]  Mifepristone for termination of early pregnancy. , 2000, FDA consumer.

[21]  S. Yeo,et al.  Pregnancy interruption using mifepristone (RU-486). A new choice for women in the USA. , 1997, Journal of nurse-midwifery.

[22]  D. Mcmaster,et al.  RU 486: An dtmtiue to Surgical Abortion , 1994 .

[23]  D. Mcmaster,et al.  RU 486: an alternative to surgical abortion. , 1994, Journal of obstetric, gynecologic, and neonatal nursing : JOGNN.

[24]  M. S. Morehead,et al.  Mifepristone , 1993, The Lancet.

[25]  M. Berer.  “Inducing a Miscarriage”: Women-Centered Perspectives on RU 486/Prostaglandin as an Early Abortion Method , 1992, Law, medicine & health care : a publication of the American Society of Law & Medicine.